PURPOSE: Peritoneal @entity82 is almost uniform feature encountered in peritoneal dialysis @entity1 . The transition of epithelial cells to mesenchymal phenotype, @entity2295 , and consequently development of peritoneal @entity82 occur due to the involvement of peritoneal membrane by various insults such as @entity5507 itself, @entity298 attacks, and exposure to bio-incompatible peritoneal dialysis fluids. Bevacizumab is a monoclonal antihuman antibody developed against vascular endothelial growth factor and can reduce @entity82 by preventing @entity2295 . There has been no study so far that demonstrates the effect of bevacizumab on peritoneal @entity82 in a @entity35 model. METHODS: A total of 41 female @entity35 albino @entity35 were divided into six groups. The control group (C) received 0.9  % isotonic saline (2  ml/day) intraperitoneally (i.p) for 21  days. @entity1216 group (CH) received 15  % @entity1068 and 0.1  % @entity5164 (CG) in saline (2  ml/day) i.p for 21  days. The resting group (R) received CG 2  ml/day i.p for 21  days. The bevacizumab-1 group (B1) received CG 2  ml/day i.p for 21  days and bevacizumab 2.5  mg/kg i.p as a single dose on day 21. The bevacizumab-2 group (B2) received CG 2  ml/day for 21  days and bevacizumab 2.5  mg/kg i.p on day 0 and day 21. The bevacizumab-3 group (B3) received bevacizumab 2.5  mg/kg i.p on day 0 and day 21. Peritoneal samples were taken from the left anterior abdominal wall. The thickness, vascularization, and @entity82 scores in the peritoneal samples were assessed using a light microscope. RESULTS: On histopathological evaluations, peritoneum thicknesses, vascularization scores, and @entity82 significantly decreased in bevacizumab groups B1 and B2. CONCLUSION: Histopathologically, bevacizumab was proven to attenuate fibrotic process in experimental peritoneal @entity1463 model.

Effect of bevacizumab, a vascular endothelial growth factor inhibitor, on a @entity35 model of peritoneal XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1216 :: ('MESH:D002710', 'Chemical') :: ['Chlorhexidine'] @entity82 :: ('MESH:D005355', 'Disease') :: ['fibrosis'] @entity5507 :: ('MESH:D014511', 'Disease') :: ['uremia'] @entity2295 :: ('MESH:D015861', 'Disease') :: ['neovascularization'] @entity1463 :: ('MESH:D012598', 'Disease') :: ['sclerosis'] @entity35 :: ('10116', 'Species') :: ['rat', 'Wistar', 'rats'] @entity1068 :: ('MESH:D000431', 'Chemical') :: ['ethyl alcohol'] @entity298 :: ('MESH:D010538', 'Disease') :: ['peritonitis'] @entity5164 :: ('MESH:C010882', 'Chemical') :: ['chlorhexidine gluconate']
@entity1463 :: (MESH:D012598,Disease) :: ['sclerosis']
